A randomised placebo-controlled double-blind study in patients with Huntington’s disease demonstrated a dose-dependent decrease in the concentration of mutant HTT in the cerebrospinal fluid (CSF) following intrathecal administration of HTTRx [55]. The gene discussed is HTT; the disease is Huntington disease.